• Welcome
  • Pherecydes Pharma at a glance
  • Press Releases
  • Documentation
    • Documentation
    • Corporate Presentation
    • Financial report
    • Regulated information
      • Shares and voting rights
      • Liquidity contract
      • Share buyback programme
      • Directors’ disclosure
    • Financial operations
  • Shareholders
    • Shareholders
    • General Meeting
      • CSM of December 15, 2022
      • OGM of May 19, 2022
    • Shareholding structure
    • Financial calendar
    • Stock information
    • Analyst coverage
  • Strategic combination
  • Contacts
  • FR
  • EN
Un phage

At the forefront of the fight
against bacterial infections

  • You are here:  
  • Strategic combination

Strategic combination

  • 02/17/2023 - 22:30

    €1.5m capital increase reserved to the historical shareholders

  • 02/16/2023 - 14:30

    Presentation of the Strategic Combination Project

  • 02/15/2023 - 22:40

    ERYTECH and PHERECYDES Announce Proposed Combination Intending to Create Global Leader in Extended Phage Therapies

  • Legal notice
  • Ask us your questions
  • Suscribe to the Newsletter
  • © Pherecydes 2023 - All rights reserved
Z33333